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Abstract
Background: As a result of extensive use of fluroquinlones and cephalosporins, urinary tract pathogens producing
extended-spectrum beta-lactamase (ESBL) pose a considerable clinical challenge in the treatment of UTIs. In the
present study we retrospectively assessed the susceptibility of E. coli strains to fosfomycin trometamol and other
antibiotics commonly used for the treatment of such infections.
Methods: A total of 908 nonreplicate clinical E. coli urinary isolates were collected from 20 Chinese hospitals over
four consecutive 1-year periods between October 2004 and June 2012. Susceptibility to antimicrobial agents fosfomycin
trometamol, piperacillin-tazobactam, cefuroxime, cefotaxime, cefepime, imipenem, amikacin, levofloxacin, and
nitrofurantoin was determined using the agar dilution method. A reference strain E. coli (ATCC 25922) was used
as a positive control. Results were analyzed using Chi-square test or Fisher’s exact tests.
Results: Fosfomycin trometamol, piperacillin-tazobactam, amikacin, and imipenem were consistently the most active
agents against most of the isolates. There was a decline in susceptibility to cefuroxime, cefotaxime, and cefepime
between 2004 and 2010. We showed that 528 of the 908 E. coli isolates (58.1%) produced ESBLs. The ESBL-positive rates
increased from 41.7% in 2004−2005 to 60.9% in 2011−2012. ESBL-producing E. coli isolates showed significantly higher
resistance rates to levofloxacin than the ESBL-negative isolates. Fosfomycin trometamol, piperacillin-tazobactam,
amikacin, and imipenem had good activity against both levofloxacin-susceptible and levofloxacin- nonsusceptible
isolates (sensitivity rate > 90%). However susceptibility of levofloxacin-resistant isolates to cefuroxime, cefotaxime,
cefepime, amikacin, and nitrofurantoin was significantly lower than that of levofloxacin-susceptible isolates.
Conclusions: Owing to the increase in the bacterial resistance across the world, the European Urology Association has
recommended fosfomycin trometamol as the drug of choice in its Guidelines on Urological Infections released in 2013.
Our results confirm this recommendation for use in China and continued monitoring of the susceptibility of E. coli to
fosfomycin trometamol is need with the widely use of the drug in China.
Background
Urinary tract infections (UTIs) are among the most com-
mon conditions, which require diagnostic and therapeutic
intervention. Escherichia coli is to date the most frequent
uropathogen, which accounted for 30.7% and 51.5% of all
UTIs in men and women, respectively, during 2010 in
China [1]. Fluoroquinolones and cephalosporins were the
most commonly used antibiotics for the treatment of UTIs
in China. However, in the recent years, many resistant
strains have emerged because of the use of broad-
spectrum cephalosporins. In particular, strains producing
extended-spectrum beta-lactamase (ESBL) pose a consid-
erable clinical challenge in the treatment of UTIs.
Fosfomycin has been extensively used in several
European countries for the treatment of uncomplicated
UTIs since 1988, but it was not available in China until
recently. This study aimed to reassess the susceptibility
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of E. coli strains isolated from patients with UTIs between
October 2004 and June 2012 to fosfomycin trometamol




A total of 908 nonreplicate clinical E. coli urinary iso-
lates were collected from 20 widely dispersed tertiary
Chinese hospitals over four 1-year periods (October
2004–September 2005, January 2007–December 2007,
July 2009–June 2010, and July 2011–June 2012) and
were sent to the Institute of Clinical Pharmacology, Peking
University First Hospital; the isolates were stored at −80°C
until further analysis. The isolates were stored at −80°C
until further analysis. The strains collected from 20
widely dispersed tertiary Chinese hospitals participat-
ing in the Ministry of Health National Antimicrobial
Resistance Surveillance Net study. These hospitals are
located in 15 different provinces in mainland China.
The number of isolates from per hospital per year was
from 4 to 26.
Antimicrobial susceptibility testing
Susceptibility to antimicrobial agents was determined
using the agar dilution method according to the Clinical
and Laboratory Standards Institute [2]. The following
antimicrobial agents were tested: fosfomycin trometamol,
piperacillin-tazobactam, cefuroxime, cefotaxime, cefepime,
imipenem, amikacin, levofloxacin, and nitrofurantoin.
ESBL)-producing isolates were detected according to
previously described methods [2]. The reference strain
E. coli ATCC 25922 was used as the positive control.
Statistical analyses
Statistical tests were performed using Social Sciences
software for Windows Version 14.0 (SPSS, Inc., Chicago,
IL, USA). Enumeration data were expressed as percentage
values. The differences in susceptibility between the groups
were compared using the Chi-square test or Fisher’s exact
test. The differences between the groups were considered
significant if the p-values were smaller than 0.05(two-sided
test). The Bonferroni method was used to adjust the signifi-
cant levels (0.05/6 = 0.0083) in multiple comparisons be-
tween any two levels of the susceptibility outcome.
Results
Comparison of antimicrobial susceptibilities between
2004 and 2012
Fosfomycin trometamol, piperacillin-tazobactam, amikacin,
and imipenem were consistently the most active agents
against most of the isolates. We observed a decline in the
susceptibility to cefuroxime, cefotaxime, and cefepime
from 2004 to 2010. In particular, the susceptibility to
cefepime decreased significantly from 88.1% during
October 2004–September 2005 to 61.5% during July
2009–June 2010 (p < 0.0001). Over the same period, the
minimum inhibitory concentration inhibiting 90% of the
strains (MIC90) increased from 16 mg/L to 64 mg/L. Sus-
ceptibility to nitrofurantoin was 78.6% during October
2004–September 2005, which increased to 83.0% during
January 2007–December 2007 and to 91.6% during July
2009–June 2010 period (p < 0.0001) (Table 1).
Comparison of antimicrobial susceptibilities to
ESBL-producing strains of E. coli
In this study, 528 E. coli isolates (58.1%) produced ESBLs.
The ESBL-positive rates were 41.7% (70/168), 58.7%
(159/271), 66.0% (173/262), and 60.9% (126/207) in the four
Table 1 Comparison of antimicrobial susceptibilities between 2004 and 2012
Antibiotica
10/2004–9/2005 (n = 168) 1/2007–12/2007 (n = 271) 7/2009–6/2010 (n = 262) 7/2011–6/2012 (n = 207)
p
S (%) MIC90 (mg/L) S (%) MIC90 (mg/L) S (%) MIC90 (mg/L) S (%) MIC90 (mg/L)
FOS 99.4 2 95.9 1 95.0 4 93.2* 8 0.030
TZP 94.0 16 97.8 8 92.7 16 94.7 8 0.058
CXM 42.3 512 32.8 512 27.5* 512 30.9 512 0.015
CTX 53.0 128 37.6* 256 30.9* 512 36.2* 512 < 0.001
FEP 88.1 16 76.4* 32 61.5*,** 64 75.4*,*** 32 < 0.001
IMP 100 0.25 99.6 0.25 99.6 0.125 99.5 0.125 1.000
AMK 94.6 4 95.6 4 92.7 8 93.2 4 0.519
NIT 78.6 64 83.0 64 91.6*,** 32 88.9* 64 < 0.001
LVX 31.0 32 28.0 32 28.2 32 32.4 32 0.693
aDrug abbreviations: FOS, fosfomycin trometamol; TZP, piperacillin-tazobactam; CXM, cefuroxime; CTX, cefotaxime; FEP, cefepime; IMP, imipenem; AMK, amikacin;
NIT, nitrofurantoin; LVX, levofloxacin.
*compared to 10/2004–9/2005, p < 0.0083.
**compared to 1/2007–12/2007, p < 0.0083.
***compared to 7/2009–6/2010, p < 0.0083.
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periods from 2004 to 2012, respectively. ESBL-producing
E. coli isolates showed significantly higher resistance rates
to cefepime and levofloxacin than the ESBL-negative
isolates. Fosfomycin trometamol, piperacillin-tazobactam,
imipenem, amikacin, and nitrofurantoin showed good
activity against both ESBL-producing and ESB-negative
isolates; the sensitivity rates were greater than 85%
(Table 2).
Comparison of susceptibility of levofloxacin-resistant
and levofloxacin-susceptible strains of E. coli to various
antimicrobial agents
Fosfomycin trometamol, piperacillin-tazobactam, amikacin,
and imipenem had good activity against both levofloxacin-
susceptible and levofloxacin- nonsusceptible isolates (sensi-
tivity rate > 90%). The rate of susceptibility to cefuroxime,
cefotaxime, cefepime, amikacin, and nitrofurantoin was
significantly lower in the levofloxacin-resistant isolates than
in the levofloxacin-susceptible isolates (p < 0.001) (Table 3).
Discussion and conclusion
E. coli plays an important role in UTI; UTI is one of the
most frequently encountered infectious diseases. Cepha-
losporins and levofloxacin are the widely used agents for
the treatment of UTI. The production of ESBLs by E.
coli is associated with the reduced susceptibility to fluor-
oquinolones and other antimicrobial agents. The resist-
ance rates of ESBL-producing E. coli to levofloxacin in
this study were higher than those reported in other stud-
ies performed in different countries [3,4]. Nitrofurantoin
were seldom used in China, it is maybe the reason that
the susceptibility of nitrofurantoin increased over time.
Our data confirm that E. coli isolated from Chinese
UTI patients remain exclusively susceptible to fosfomy-
cin trometamol. In addition, the ESBL-producing and
levofloxacin-resistant strains of E. coli were susceptible
to fosfomycin trometamol. Our results are similar to
those reported in recent studies on the same pathogens
isolated from other areas of the world [5,6].
Fosfomycin trometamol was excreted renally within
48 hours and urinary titres showed that concentra-
tions > 128 mg/L, sufficient to inhibit most urinary
pathogens, were maintained for 24 to 48 hours after a
single oral dose (≅3g fosfomycin), but the mean peak
plasma concentrations were only 22 to 32 mg/L [7]
The European Urology Association has recommended
fosfomycin trometamol, nitrofurantoin and pivmecilli-
nam as the drug of choice in its Guidelines on Urological
Infections released in 2013 [8]. An uncontrolled and
multicentre study showed clinical efficacy rates for
acute uncomplicated cystitis, recurrent lower urinary
tract infection and complicated lower urinary tract in-
fection were 94.71, 77.22% and 62.69% [9]. Continued
monitoring of the susceptibility of E.coli to fosfomycin
trometamol is needed with the widely use of the drug
in China.
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Table 2 Comparison of the susceptibilities of






(n = 380) p
S (%) MIC90 (mg/L) S (%) MIC90 (mg/L)
FOS 93.8 2 98.4 1 0.001
TZP 95.3 16 95.8 8 0.707
IMP 100 0.25 99.2 0.25 0.073
AMK 92.8 8 95.8 4 0.061
NIT 86.2 64 85.8 64 0.869
LVX 17.2 32 46.8 32 < 0.001
aDrug abbreviations: FOS, fosfomycin trometamol; TZP, piperacillin-tazobactam;
IMP, imipenem; AMK, amikacin; NIT, nitrofurantoin; LVX, levofloxacin;
ESBL, extended-spectrum beta-lactamase.
Table 3 Comparison of susceptibility of levofloxacin-
susceptible and levofloxacin- nonsusceptible strains of
Escherichia coli to various antimicrobial agents
Antibiotica
LVX-S (n = 269) LVX-NS (n = 639)
p
S (%) MIC90 (mg/L) S (%) MIC90 (mg/L)
FOS 98.5 0.5 94.5 4 0.007
TZP 95.9 4 95.3 8 0.688
CXM 63.2 512 19.7 512 < 0.001
CTX 64.7 128 27.1 512 < 0.001
FEP 91.4 8 66.7 64 < 0.001
IMP 100 0.25 99.5 0.25 0.559
AMK 98.9 2 92.0 8 < 0.001
NIT 96.3 16 81.7 64 < 0.001
LVX-S, levofloxacin-susceptible; LVX-NS, levofloxacin-resistant or intermediately.
aDrug abbreviations: FOS, fosfomycin trometamol; TZP, piperacillin-tazobactam;
CXM, cefuroxime; CTX, cefotaxime; FEP, cefepime; IMP, imipenem; AMK, amikacin;
NIT, nitrofurantoin; LVX, levofloxacin.
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